| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2817954cd008bcd609a4c4eb49050be |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-92 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 |
| filingDate |
1992-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e86b78d833f4f0cf67fdf441fc53640
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e34b88b40988e8e365d99b0928c905b1 |
| publicationDate |
1993-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2117073-A1 |
| titleOfInvention |
Mutated growth factor receptor as a drug and its use for the treatment of cancer |
| abstract |
Abstract The present invention relates to mutated growth factor receptors which are suited as a drug. The mutated growth factor receptors as especially advantageous for the treatment of cancer diseases, in particular of those types of cancer, in which the overactivity of growth factor receptors plays a role in the development of cancer and other diseases based on the overactivity of the receptors. Mutants of the EGF receptor are disclosed as an especially effective drug for the treatment of cancer, in which the tyrosine kinase activity of the wild-type receptor was eliminated by a point mutation or deletion in the tyrosine kinase domain. |
| priorityDate |
1991-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |